Key statistics
On Wednesday, Annovis Bio Inc (ANVS:NYQ) closed at 8.05, 77.70% above the 52 week low of 4.53 set on Jul 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.33 |
---|---|
High | 8.48 |
Low | 7.99 |
Bid | 7.95 |
Offer | 8.30 |
Previous close | 8.33 |
Average volume | 136.14k |
---|---|
Shares outstanding | 13.05m |
Free float | 10.24m |
P/E (TTM) | -- |
Market cap | 108.74m USD |
EPS (TTM) | -4.42 USD |
Data delayed at least 15 minutes, as of Oct 10 2024 00:00 BST.
More ▼
Announcements
- Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases
- Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations
- Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra
- Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference
- Annovis Bio Reports Second Quarter Financial Results and Provides Business Update
- Annovis’ Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist
- Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap
- Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap
- Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team
- Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap
More ▼